摘要:
The present invention relates to novel compounds, compositions containing same and methods for inhibiting STAT3 and/or STAT5 activity or for the treatment of a STAT3 or STAT5-dependent cancer using said compounds; or a pharmaceutically acceptable salt, solvate or prodrug thereof.
摘要:
Flame retardants are described, comprising A. at least one organic phosphonate of formula (I), wherein R is hydrogen, C1-C20alkyl, unsubstituted or C1-C4alkyl-substituted phenyl or naphthyl, R' is hydrogen, C1-C20alkyl, unsubstituted or C1-C4alkyl-substituted phenyl or naphthyl or M1r+/r, n is an integer from 0 to 6, M1r+ is an r-valent metal ion or the ammonium ion, r is an integer from 1 to 4, R13 is isopropyl, isobutyl, tert-butyl, cyclohexyl or is cycloalkyl substituted by from 1 to 3 C1-C4alkyl groups, R14 is hydrogen, C1-C4alkyl, cycloalkyl or is cyclohexyl substituted by from 1 to 3 C1-C4alkyl groups, and R15 is hydrogen, C1-C18alkyl, trimethylsilyl, benzyl, phenyl or sulfonyl; and B. at least one flame retardant component based on a nitrogen compound, and also the use thereof in synthetic polymers.
摘要:
The present invention relates to novel diarylurea derivatives represented by general formula (I) useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.
摘要:
Compounds, compositions and methods are provided for modulating the activity of protein tyrosine phosphatases, including PTP-1B. In one embodiment, the compounds are N,N-dibenzylarylsulfonamides.
摘要:
The present invention relates to novel diarylurea derivatives represented by general formula (I) useful as chloride channel blockers. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of bone metabolic diseases, diseases responsive to modulation of the mast cell or basophil activity, diseases responsive to inhibition of angiogenesis, or sickle cell anaemia, and to pharmaceutical compositions comprising the compounds of the invention.
摘要:
Immunoregulatory compounds are disclosed of the formula: and as well as the pharmaceutically acceptable salts and hydrates thereof, are disclosed. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.